Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020



Jason Slingsby

Jason Slingsby

Chief Business Officer, Oxford Biomedica
Jason joined Oxford BioMedica in 2015 and has been Chief Business Officer since 2018.  He has 20 years’ experience in the biotechnology industry in biologics, vaccines and gene therapy.  He has worked in international business development roles at Sosei Co., Ltd, and Intercell AG and was co-founder and CEO of ProtAffin AG, a venture capital backed company in Austria and UK.  Jason was awarded a 1st class BA (Hons) in Biochemistry from Magdalen College, Oxford University and also completed an PhD in complex disease genetics from Imperial College London.  Jason was awarded an MBA with distinction from London Business School.
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd